About this trial
To evaluate the clinical efficacy and health economic advantages of Lung Replenishing and Kidney Enhancing Formula for the treatment of patients with frequent acute exacerbations in the stabilized phase.
Eligibility criteria
Qualifiers
Patients diagnosed with COPD at a stable stage.
Stable COPD patients with frequent acute exacerbation.
Age 40-80 years old.
The condition was stable 4 weeks before enrollment.
Disqualifiers
complicity with other diagnosed and clinically significant respiratory diseases, including but not limited to: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary hypertension, pulmonary embolism, pneumothorax, pleural effusion, interstitial lung disease, or other active pulmonary diseases requiring intervention.
Patients with severe or acute cardiovascular and cerebrovascular diseases (acute cardiovascular and cerebrovascular events, malignant arrhythmias, unstable angina pectoris, cardiac function grade 3 or above, uncontrolled hypertension, etc.).
Complicated with severe liver and kidney disease (severe liver disease refers to cirrhosis, portal hypertension and varicose vein bleeding, serious kidney disease including dialysis, kidney transplantation).
Any item of liver function index (ALT, AST) exceeds the upper limit of normal reference value by 1.5 times, and renal function index Scr exceeds the upper limit of normal reference value.
Trial design
Treatments tested in this trial
- Bufei Yishen Prescription Granule
Treatment groups
Locations
Sponsors and collaborators
Henan University of Traditional Chinese Medicine
Lead sponsor
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Collaborator
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Collaborator